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Fludarabine and cyclophosphamide based reduced intensity conditioning
(RIC) regimens reduce rejection and improve outcome in Indian patients
undergoing allogeneic stem cell transplantation for severe aplastic anemia
B George, V Mathews, A Viswabandya, ML Kavitha, A Srivastava and M Chandy
Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India
Thirty-five patients (25 men and 10 women) with a median
age of 20 years with severe aplastic anaemia (SAA)
underwent HLA identical stem cell transplantation
(HSCT) using a combination of fludarabine and cyclo-
phosphamide7anti-thymocyte globulin between 2004 and
2006. Cyclosporine and mini methotrexate were used as
GVHD prophylaxis. Graft source included peripheral
blood stem cells (28) or G-CSF stimulated bone marrow
(7). Two patients expired o7 days post-HSCT while 32
(91.5%) patients engrafted with a median neutrophil and
platelet engraftment time of 12 days each. Three patients
(8.5%) developed veno-occlusive disease while acute
GVHD occurred in 29% of evaluable patients, with
chronic GVHD in 32%. At a mean follow-up of 22
months, 29 (82.8%) are alive and well. When compared
with 26 patients previously transplanted using Cy200/
antilymphocyte globulin, there was faster neutrophil
engraftment (12 vs 16 days; P¼ 0.002) with significantly
lower rejection rates (2.9 vs 30.7%; P¼ 0.003) and a
superior event-free (82.8 vs 38.4%; P¼ 0.001) and overall
survival (82.8 vs 46.1%; P¼ 0.005). A combination of
fludarabine with cyclophosphamide7anti-thymocyte glo-
bulin reduces rejection and improves overall and event-free
survival in Indian patients undergoing HSCT for severe
aplastic anaemia.
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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT)
is the treatment of choice for young patients with severe
aplastic anaemia (SAA) who have an HLA-matched related
donor, with disease-free survival rates ranging between 60
and 95% in various studies.1–5 A number of factors have
been previously identified as affecting survival after HSCT
including older age, interval between diagnosis and
transplantation, number of transfusions before transplant
and use of cyclosporine (CsA) for graft-versus-host disease
(GVHD) prophylaxis.2,6,7 Graft rejection is an important
cause of increased morbidity and mortality following
HSCT for SAA, with rejection rates ranging from 10 to
30%.8 Factors associated with high rejection rates include a
long interval between diagnosis and transplant, increased
number of pre-transplant blood transfusions (420), pre-
transplant infections and multiple treatments including
immunosuppressive therapy before transplant.8–11 In many
developing countries, there is usually a time delay between
diagnosis and HSCT due to economic and resource
constraints and hence patients have multiple risk factors
at the time of HSCT leading to high rejection rates and
poor survival. Strategies used to reduce graft rejection
include the addition of radiation therapy or anti-thymocyte
globulin (ATG) to the basic conditioning regime of
cyclophosphamide or the administration of donor buffy
coats post transplant, but high rejection rates are still seen
in developing countries with these protocols.12 Fludarabine
is a novel purine analogue that has been used for non-
myeloablative transplants in older patients and has the
advantage of reduced toxicity and increased immunosup-
pression. There have been a few reports on the use of
fludarabine-based protocols in patients with aplastic
anaemia including Fanconi’s anaemia, resulting in reduced
rejection and low toxicity.13–15 We present our data on the
use of a combination of fludarabine and cyclophospha-
mide, with, or without ATG, as conditioning therapy for
HLA matched allogeneic stem cell transplants in aplastic
anaemia.
Patients and methods
All patients who underwent HLA identical allogeneic
HSCT for aplastic anaemia at the Christian Medical
College Hospital between 2004 and 2006 were included in
this study. All patients had a six antigen HLA matched
sibling or family donor. Written informed consent was
obtained from all patients before HSCT.
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High-risk patients were identified as those with any of the
following risk factors –
(a) Active infection (bacterial or fungal) at the time of
BMT.
(b) Failed previous immunosuppressive therapy (ALG/
ATG or cyclosporine).
(c) Number of previous transfusions 420.
Transplant
All patients were nursed in HEPA-filtered rooms. The
conditioning regimen used was a combination of Fludar-
abine and Cyclophosphamide with, or without ATG.
Graft source and engraftment
G-CSF stimulated peripheral blood stem cells was the
preferred graft source. G-CSF stimulated bone marrow was
used with small paediatric donors. Neutrophil engraftment
was defined as the first of three consecutive days with ANC
4500/mm3, while platelet engraftment was defined as the
first of three consecutive untransfused platelet counts
420 000/mm3. Chimerism analysis using VNTRs was done
at day 30 post-HSCT. In patients who had a sex-
mismatched transplant, chimerism was assessed with FISH
for X and Y chromosomes. Repeat chimerism analysis was
carried out after 1 month if the initial chimerism showed a
mixed picture.
Antimicrobial prophylaxis
No antibacterial or antifungal prophylaxis was used.
Acyclovir was started on day þ 1 as herpes prophylaxis
and Sulfamethoxazole/Trimethoprim as prophylaxis
against pneumocystis carinii was started once the WBC
count was 43 109/l with ANC 41.5 109/l. PCR for
CMV infection was checked serially starting day þ 30, and
pre-emptive therapy with ganciclovir was instituted for
CMV PCR-positive patients.
GVHD prophylaxis
GVHD prophylaxis consisted of CSA alone or in
combination with short course MTX. CSA was started at
a dose of 3mg/kg/day intravenously in two divided doses,
on day 1, and changed to the oral route once the counts
had improved and the patient was able to take oral
medication. CSA was continued at full doses for a period of
6 months and then tapered, in the absence of GVHD, over
a period of 6 months to stop at 12 months following BMT.
Intravenous MTX was given initially at a dose of 5mg/m2
on days þ 1, þ 3 and þ 6 followed by folinic acid rescue
24 h later. From October 2004, the dose of MTX was
increased to 10mg/m2 on day þ 1 followed by 7mg/m2 on
days þ 3 and þ 6. Individual doses of methotrexate were
omitted in the presence of severe mucositis, bleeding or
jaundice. GVHD was diagnosed on tissue biopsy – either
skin, upper gastrointestinal or rectal biopsy, and treatment
was initiated on clinical grounds or because of a positive
biopsy, with either intravenous dexamethasone or methyl
prednisolone, which was converted into oral steroids once
the symptoms of GVHD had improved. If the patient was
steroid refractory, second-line therapy included ATG,
antilymphocyte globulin (ALG), anti-T cell antibody
(OKT3), mycophenolate or daclizumab. Chronic GVHD
was treated with a combination of cyclosporine and oral
steroids. In patients where improvement was not satisfac-
tory, azathioprine or thalidomide were considered.
Statistical analysis
Event-free survival (EFS) was calculated as survival in the
absence of death or relapse. Overall survival (OS) included
all patients who were alive on the last evaluation. For
comparison of dichotomous variables, a w2 test was done
while continuous variables were compared using either a
Student’s t-test or a Mann–Whitney U-test as was deemed
appropriate. The probability of OS and DFS were
estimated using Kaplan–Meier method. The prognostic
relevance of clinical and biological variables was studied
using univariate and multivariate Cox regression analysis.
For all the tests, a two-sided P-value of 0.05 or less was
considered statistically significant.
Results
There were 35 patients (25 men and 10 women) including
12 children, with a median age of 20.8 years (range: 5–43).
The median time from diagnosis to HSCT was 10.4 months
(range: 2–84) while the median number of transfusions
before HSCT was 17 (range: 2–140). At the time of HSCT,
18 patients (51.4%) were considered as high risk (Table 1).
Risk factors included active infection (bacterial or fungal)
in 10, 420 transfusions in two, failed immunosuppression
(ALG or CSA) in four and a second BMT in two. Two
patients (6.6%) were on ventilatory support at the time of
the graft infusion.
Conditioning regimens used for transplant consisted of
Fludarabine 180mg/m2 over 6 days (days 7 to 2)þ
cyclophosphamide 120mg/kg over 2 days (days 3 and 2)
in 24 patients (Flu-Cy protocol) and fludarabine 180mg/m2
over 6 days (days 10 to 5)þ cyclophosphamide 120mg/
kg over 2 days (days 6 and 5)7ATG (ATGAM) 10mg/
kg/day for 4 days (days 4 to 1) in 11 (Flu-Cy-ATG
protocol) patients.
Engraftment
The graft source was peripheral blood stem cells (PBSC) in
28 (80%) patients and G-CSF stimulated bone marrow in
Table 1 Pre-transplant characteristics of patients undergoing
HSCT with a combination of Fludarabine and Cyclophosphami-
de7ATG
Flu/Cy7ATG (n¼ 35)
Median age (years) 20.8 (5–43)
Sex
Male 25
Female 10
Median time from diagnosis to BMT months 10.4 (2–84)
Median number of transfusions before BMT 17 (2–140)
High-risk patients 18 (51.4%)
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seven (20%). The median cell dose was 5.3 108 total
nucleated cells/kg for bone marrow (range: 2.1–9.9) and
6.1 108 MNC/kg for PBSC (range: 1.9–12.3). Thirty-two
(91.5%) engrafted with two patients (5.7%) expiring o7
days post-BMT, while one patient (2.8%) had primary
graft rejection. The median time to ANC 4500/mm3 was
12.3 days (range: 9–19), ANC 41000/mm3 was 13.6 days
(range: 10–19) and platelet count 420 000/mm3 was 12.4
days (range: 8–32) (Table 2). Post-transplant chimerism
data were available for 31 evaluable patients. The day 30
chimerism showed 100% donor chimerism in 30 patients
(96.7%) while mixed chimerism was seen in one patient
(3.3%). This patient continued to show mixed chimerism
on last follow-up (97.4% donor cells) with normal blood
counts.
Toxicity and GVHD
Three patients (8.5%) developed veno-occlusive disease of
the liver. All responded well to supportive therapy.
Cyclosporine in combination with short course MTX
was used in 31 patients (88.5%) while cyclosporine alone or
combined with methylprednisolone was used as GVHD
prophylaxis in four patients (13.4%). Of the 31 patients
who were evaluable for GVHD, nine (29%) developed
acute GVHD. Of these, seven had grade I and II GVHD
while one each had grade III and grade IV GVHD. Seven
patients (77.7%) responded to a combination of cyclos-
porine and prednisolone while two (22.3%) expired owing
to GVHD or associated infection. Twenty-five patients
were evaluable for chronic GVHD, and of these, eight
(32%) developed chronic GVHD, which was limited in all
patients. All improved with a combination of cyclosporine
and prednisolone. Comparing the graft source, the
incidence of acute GVHD was not significantly higher with
the use of PBSC (31 vs 20%; P¼ 1.000) nor was the
incidence of chronic GVHD higher (30 vs 40%; P¼ 0.172).
Survival
Four patients (11.4%) expired o2 weeks following HSCT,
while the day 100 transplant-related mortality was 17.1%.
At a median follow-up of 22 months, 29 (82.8%) are alive
and well. Among the 17 patients who did not have any
high-risk features at the time of HSCT, the overall survival
was 100%.
We compared engraftment, toxicity and survival between
patients who received ATG (n¼ 11) and those who did not
(n¼ 24). There was no difference in the median time to
neutrophil and platelet engraftment, and the incidence of
acute GVHD and survival (Table 3) were also similar
between both groups.
A historical comparison was carried out with 26 patients
who underwent allogeneic HSCT for aplastic anaemia at
our centre between 1990 and 2004 using either cyclopho-
sphamide (200mg/kg over 4 days) alone (n¼ 2) or in
combination with ALG (Lymphoglobuline, Pasteur Mer-
ieux 90mg/kg over 3 days) (n¼ 24) as the conditioning
regimen. Bone marrow was used as the graft source
in all patients. Table 4 shows the comparative data bet-
ween groups. The number of patients in the high-risk
category was similar (42% in the Cy200/ALG group;
51% in the Flu/Cy group) although the number of trans-
fusions in the past, was significantly higher in the
fludarabine group (Table 4). There was faster neutro-
phil (12.3 vs 16.8 days; P¼ 0.002) and platelet (12.4 vs
26.2 days; P¼ 0.000) engraftment in the fludarabine group,
with significantly lower rejection rates (2.9 vs 30.7%;
P¼ 0.003) as compared to the Cy200/ALG group. There
was only one primary graft failure in the fludarabine group
as compared to three primary graft failures and five
secondary rejections in the Cy/ALG group. OS was
significantly higher in the fludarabine group (82.8 vs
46.2%; P¼ 0.017) as compared to the Cy200/ALG group
(Figure 1) as was the event-free survival (EFS) (82.8 vs
38.5%; P¼ 0.004) (Figure 2).
Discussion
In developing countries, there is usually a delay between the
diagnosis of SAA and the HSCT procedure during which
patients receive multiple transfusions, develop recurrent
infections or have major bleeding episodes. Many patients
Table 2 Engraftment, toxicity and survival
Flu/Cy7ATG (n¼ 35)
Engraftment 32 (91.5%)
ANC4500 (days) 12.3 (9–19)
ANC41000 (days) 13.6 (10–19)
Plt count420 000 (days) 12.4 (8–32)
Acute GVHD 9/31 (29%)
Chronic GVHD 8/25 (32%)
Toxicity (VOD/HC) 3/35 (8.5%)
EFS 29/35 (82.8%)
Overall survival 29/35 (82.8%)
Abbreviations: EFS¼ event-free survival; VOD¼ veno-occlusive disease.
Table 3 Comparison of engraftment, GVHD and survival in the Flu-Cy vs Flu-Cy-ATG group
Flu/Cy (n¼ 24) Flu/Cy/ATG (n¼ 11) P-value
Cell dose ( 108 TNC/kg) 6.1 (BM), 6.8a (PBSC) 5.7 (BM)
ANC4500/mm3 (days) 1272.2 12.872.6 0.190
ANC41000/mm3 (days) 13.172.5 14.572.6 0.113
Platelet count420 000/mm3 (days) 11.375.9 14.575.2 0.069
Acute GVHD 4/20 (20%) 5/11 (45.4%) 0.217
OS 19/24 (79.1%) 10/11 (90.9%) 0.260
Abbreviation: TNC¼ total nucleated cells.
aDenotes mononuclear cells/kg (MNC/kg).
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may also receive immunosuppressive therapy with either
ALG or cyclosporine and are referred for transplant only if
these fail. All of these factors can contribute to a poor
outcome with HSCT, related mainly to graft rejection and
infection. Fludarabine-based protocols have been used in
both related and unrelated transplants for aplastic anaemia
with reduced rejection rates and minimal GVHD.14,16,17 We
started using the fludarabine-based protocol reported by
Slavin18 for patients with aplastic anaemia since the
standard CY200/ALG protocol was associated with high
rejection rates. The busulfan in the original protocol was
substituted with cyclophosphamide in 2004 since we
believed that ‘immunosuppression’ rather than ‘myeloabla-
tion’ was the key component of a good conditioning
regimen for aplastic anaemia. Using a combination of
fludarabine, cyclophosphamide7ATG, we have been able
to reduce rejection rates to o3% which is significantly
lower than in our historical controls (30.7%) when a
combination of cyclophosphamide and ATG was used for
conditioning.
Gupta et al.19 used a combination of cyclophosphamide
and in vivo anti-CD52 monoclonal antibodies in heavily
transfused patients with aplastic anaemia and showed
adequate engraftment with a low incidence of GVHD, but
graft rejection rates were still very high (24%). The low
incidence of GVHD in our study is similar to data available
on fludarabine based transplants in aplastic anaemia from
India, Mexico and Israel,20–23 but it is very different from
NIH data24 where the incidence of acute GVHD II–IV was
65% despite using Cyclosporine7Methotrexate as GVHD
prophylaxis and equine ATG as part of the conditioning
regimen. In our series, the exclusion of ATG from the
conditioning regimen did not adversely affect the incidence
of rejection or GVHD (45.4% with ATG vs 20% without
ATG) despite PBSC being the graft source in 80% of
patients. Garza et al.25 in their study on multi-transfused
patients with aplastic anaemia also suggest that the use of
PBSC without the use of ATG was associated with a good
outcome. We preferred to use PBSC as the graft source
since 450% of patients were considered high risk (either
multiple transfusions or active infection at time of HSCT)
and hence a higher cell dose (including CD34 dose) should
reduce the risk of rejection while a faster neutrophil
engraftment would help in reducing infection related
mortality. Retrospective data analysis from the IBMTR/
EBMT seemed to suggest a worse outcome with the use of
PBSC26 but in our small cohort of patients, the use of
PBSC was not associated with an increased risk of GVHD
or inferior survival. A longer follow-up will help us in
studying the long-term impact of using PBSC. Whether the
presence of fludarabine in the conditioning regimen had a
moderating influence on GVHD and hence on long-term
survival will need to be addressed in larger studies. The
long-term remission rates of 480% in this high-risk
Table 4 Pre-transplant characteristics, engraftment, rejection, toxicity and survival between Fludarabine and Cy200/ALG group
Fludarabine group (n¼ 35) Cy200/ALG group (n¼ 26) P-value
Median age (years) 20.8710.7 17.778.3 0.293
Time interval from diagnosis to BMT 11.7 months 6.5 months 0.144
Number of transfusions before BMT 17.4 10.1 0.042
‘High-risk’ patients 18 (51.4%) 11 (42.3%) 0.310
ANC4500/mm3 (days) 12.372.3 16.879.3 0.002
ANC41000/mm3 (days) 13.672.6 17.979.5 0.017
Platelet count420 000/mm3 (days) 12.475.8 26.2719.1 0.000
Acute GVHD 9/31 (29%) 6/22 (27.2%) 0.767
Rejection 1/35 (2.9%) 8/26 (30.7%) 0.003
DFS 29/35 (82.8%) 10/26 (38.5%) 0.001
OS 29/35 (82.8%) 12/26 (46.2%) 0.005
Abbreviation: DFS¼ disease-free survival.
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population make this protocol an attractive option for
allogeneic HSCT, especially in developing countries. These
data compare favourably with EBMT data and other
single-centre studies where long-term survival is 65–75% in
patients undergoing HLA identical sibling transplantation
using either Cy/ATG or fludarabine-based regimens.27–31
Interestingly, among patients who fulfilled the criteria for
low-risk, survival rates were 100% suggesting that a
fludarabine based protocol may be useful even in patients
who are minimally transfused.
In conclusion, a combination of fludarabine with
cyclophosphamide7ATG ensures adequate engraftment
with minimal toxicity and low rejection rates in patients
with aplastic anaemia. The use of fludarabine and the need
for ATG in standard conditioning regimens for aplastic
anaemia must be further explored in larger studies.
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